Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0

被引：1
|
作者：
Vairetti, Mariapia [1 ]
Colucci, Giuseppe [2 ]
Ferrigno, Andrea [1 ]
机构：
[1] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy
[2] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Div Gastroenterol & Hepatol, I-20122 Milan, Italy
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 14期
关键词：
STEATOSIS; MODEL; DIET; ACID;
D O I：
10.3390/ijms23147894
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
    Radwan, Mohamed M.
    Radwan, Basil M.
    Nandipati, Kalyana C.
    Hunter, William J., III
    Agrawal, Devendra K.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (08) : 727 - 738
  • [32] Effect of Roux-en-Y Reconstruction on Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH)
    Kashihara, Hideya
    Yoshikawa, Kozo
    Higashijima, Jun
    Nishi, Masaaki
    Takasu, Chie
    Shimada, Mitsuo
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (04) : E58 - E59
  • [33] Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis
    Kluwe, J
    Lohse, AW
    INTERNIST, 2005, 46 (12): : 1324 - +
  • [34] Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Younossi, Zobair M.
    Loomba, Rohit
    Rinella, Mary E.
    Bugianesi, Elisabetta
    Marchesini, Giulio
    Neuschwander-Tetri, Brent A.
    Serfaty, Lawrence
    Negro, Francesco
    Caldwell, Stephen H.
    Ratziu, Vlad
    Corey, Kathleen E.
    Friedman, Scott L.
    Abdelmalek, Manal F.
    Harrison, Stephen A.
    Sanyal, Arun J.
    Lavine, Joel E.
    Mathurin, Philippe
    Charlton, Michael R.
    Chalasani, Naga P.
    Anstee, Quentin M.
    Kowdley, Kris V.
    George, Jacob
    Goodman, Zachary D.
    Lindor, Keith
    HEPATOLOGY, 2018, 68 (01) : 361 - 371
  • [35] Role of plasma FGF21 as a biomarker for nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH)
    Bril, Fernando
    Lomonaco, Romina
    Orsak, Beverly
    Chang, Zhi
    Ortiz-Lopez, Carolina
    Hecht, Joan
    Tio, Fermin
    Cusi, Kenneth
    HEPATOLOGY, 2013, 58 : 487A - 487A
  • [36] Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Brown, Gregory Thomas
    Kleiner, David E.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08): : 1080 - 1086
  • [37] Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
    Romero-Gomez, Manuel
    Kachru, Nandita
    Zamorano, Meritxell Ascanio
    Darba, Josep
    Shreay, Sanatan
    MEDICINE, 2020, 99 (50) : E23506
  • [38] Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Takahashi, Yoshihisa
    Fukusato, Toshio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (42) : 15539 - 15548
  • [39] Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic steatohepatitis
    Manne, Vignan
    Handa, Priya
    Kowdley, Kris V.
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 23 - +
  • [40] Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Yoshihisa Takahashi
    Toshio Fukusato
    World Journal of Gastroenterology, 2014, (42) : 15539 - 15548
12345